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ABSTRACT
Background: Little information is available on B vitamin concentra-
tions in human milk or on how they are affected by maternal B vitamin
deficiencies, antiretroviral therapy, or maternal supplementation.
Objective: The objective was to evaluate the effects of antiretrovi-
ral therapy and/or lipid-based nutrient supplements (LNSs) on B
vitamin concentrations in breast milk from HIV-infected women
in Malawi.
Design: Breast milk was collected from 537 women recruited within
the Breastfeeding, Antiretrovirals, and Nutrition study at 2 or 6 wk
and 24 wk postpartum. Women were assigned to receive antiretrovi-
rals and LNSs, antiretrovirals only, LNSs only, or a control. Antire-
trovirals and LNSs were given to the mothers from weeks 0 to 28.
The antiretrovirals were zidovudine/lamivudine and nelfinavir or
lopinavir/ritonavir. LNSs provided 93–118% of the Recommended
Dietary Allowances of thiamin, riboflavin, niacin, pyridoxine, and
vitamin B-12. Infants were exclusively breastfed.
Results: LNSs increased milk concentrations of all vitamins except
thiamin, whereas antiretrovirals lowered concentrations of nicotin-
amide, pyridoxal, and vitamin B-12. Although antiretrovirals alone
had no significant effect on riboflavin concentrations, they nega-
tively affected the LNS-induced increase in this vitamin. Thiamin
was not influenced by the study interventions. Concentrations of all
B vitamins were much lower than usually accepted values.
Conclusions: All B vitamins were low in milk, and all but thiamin
were increased by maternal supplementation with LNSs. Antire-
trovirals alone decreased concentrations of some B vitamins in
milk. When LNS was given in addition to antiretrovirals, the neg-
ative effect of antiretrovirals offset the positive effect of LNSs for
all vitamins except thiamin. This trial was registered at clinical-
trials.gov as NCT00164762. Am J Clin Nutr 2015;102:1468–74.
Keywords: antiretrovirals, B vitamins, breast milk, human milk,
ultraperformance liquid chromatography tandem mass spectrometry
INTRODUCTION
The WHO recommends exclusive breastfeeding (EBF)10 for
the first 6 mo of life based on its positive benefits for infant
health and development, and the assumption that it provides
adequate amounts of all nutrients, including micronutrients (1).
However, breastfeeding increases the risk of mother-to-child
HIV transmission. Several studies have indicated that postnatal
HIV-1 transmission from mother to child can be reduced by
antiretroviral drugs given to the mother or infant (2–9). These
findings led to the current WHO recommendations for HIV-
infected mothers to breastfeed exclusively for 6 mo and to
continue breastfeeding to 12 mo in conjunction with taking
antiretrovirals (either the mother or infant) for the duration of
breastfeeding (1).
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HIV infection increases energy and nutrient requirements,
which makes it more challenging to meet the needs of both the
mother and the infant (10, 11). No information is available
concerning whether antiretroviral therapy provided to HIV-
infected mothers during lactation affects micronutrient con-
centrations in breast milk. This would be of greatest concern
in areas where maternal micronutrient status is poor because
inadequate intake or the status of many micronutrients, especially
B vitamins, adversely affects the amounts secreted in milk (12).
Lipid-based nutrient supplements (LNSs) could increase the
supply of energy and micronutrients to the HIV-positive
mother, and the secretion of some micronutrients in her milk;
however, the efficacy of this approach has not been evaluated
(13, 14).
This study examines the effects of antiretrovirals and LNSs on
thiamin, riboflavin, nicotinamide, pyridoxal, and vitamin B-12 con-
centrations in the breast milk of HIV-infected Malawian mothers.
Values for the concentration of each B vitamin were compared with
those published for milk fromwell-nourishedwomen and used to set
Adequate Intakes (AIs) for infants aged 0–6 mo (15).
METHODS
Subjects and sample collection
The Breastfeeding, Antiretrovirals, and Nutrition study pop-
ulation consisted of HIV-infected women recruited from 4 an-
tenatal clinics in Lilongwe, Malawi, between 2004 and 2009. The
recruitment methods and flow of participants have been described
in detail elsewhere (8, 11, 16, 17). Mothers in this study were
counseled to exclusively breastfeed for 24 wk and then to rapidly
wean from 24 to 28 wk, in accordance with WHO recommen-
dations at the time the study began (16, 18).
At delivery, women and their infants were randomly assigned
by using the permuted block method to a 2-arm (LNSs or no
LNSs) by 3-arm (maternal antiretrovirals, infant antiretrovirals,
or neither) factorial design (Supplemental Figure 1). For the
current analysis of the effects on breast milk, no differentiation
was made between infants treated or not treated with antiretrovirals,
which resulted in 4 intervention groups. After screening and
enrollment by study nurses, a data manager generated the random
allocation sequence. Study pharmacists assigned participants to
interventions via sequentially numbered envelopes and distributed
antiretrovirals and LNSs during the scheduled visits at 0, 1, 2, 4, 6,
8, 12, 18, 21, 24, and 28 wk postpartum. The LNS was manufac-
tured by Nutriset in France (www.nutriset.fr). Each sachet contained
70 g, and the women were instructed to consume 2 sachets/d, which
provided 746 kcal/d and approximately the Recommended Dietary
Allowance for most micronutrients (Table 1). However, the LNS
provided no vitamin A because of concerns that supplements could
increase HIV transmission through breast milk (19, 20). The anti-
retroviral drug regimen for mothers consisted of zidovudine and
lamivudine (Combivir) plus either nevirapine (until January 2005),
nelfinavir (from January 2005 to February 2006), or lopinavir and
ritonavir (Kaletra, Abbott; from February 2006 until study com-
pletion). In addition, 2 kg maize flour was provided weekly to all
participants for family consumption.
Maternal reports of LNS consumption were taken at 1, 4, 8, 12,
and 21 wk. Breast milk was manually expressed by the participants,
producing opportunistic samples during the regular study visits at
weeks 2, 6, and 24. The milk was immediately frozen after col-
lection. The 6-wk samples were obtained when a 2-wk sample was
unavailable or the infant had insufficient plasma at 2 wk. The
sample size was predetermined by the number of participants
providing milk, maternal, and infant plasma samples; participants
were prioritized for selection in the micronutrient subsample if
they had anthropometric and dietary intake data. They were ex-
cluded from the subsample if the infants became HIV-positive or
were multiple births. The larger study’s sample size calculations
were previously described in detail (16). As with all food-based
nutrition supplement trials, participants and physicians could not
be blinded to the study arm. Outcome assessors and data analysts
were not informed about the allocation strategy.
No milk samples were collected before supplementation with
LNS; therefore, no true baseline concentrations were available
for control in the statistical analyses. Samples were shipped on
dry ice to the CDC in Atlanta and stored at2808C until analyzed
at the USDA/Agricultural Research Service, Western Human
Nutrition Research Center in Davis, CA.
This research was approved by the Malawi National Health
Science Research Committee, the Institutional Review Boards at
the University of North Carolina Chapel Hill, the CDC, and the
University of California, Davis. The trial was monitored for
safety and efficacy by the National Institute of Allergy and In-
fectious Diseases Vaccine and Prevention Data and Safety
Monitoring Board.
Biochemical analyses
Free thiamin, riboflavin, flavin adenine dinucleotide (FAD), nic-
otinamide, and pyridoxal in milk were analyzed simultaneously by
TABLE 1
Composition of the lipid-based nutrient supplement formulated for use by









Protein, g — 20.8
Iron, mg 9 15
Zinc, mg 12 19
Phosphorus, mg 700 1200
Selenium, mg 70 75
Thiamin, mg 1.4 1.6
Riboflavin, mg 1.6 1.8
Niacin, mg equivalent 17 20
Pyridoxine, mg 2.0 2.2
Vitamin B-12, mg 2.8 2.6
Ascorbic acid, mg 120 100
a-Tocopherol, mg 19 12
Folic acid, mg 500 300
Iodine, mg 290 200
Potassium, g 5.1 1.1
Magnesium, mg 310 124
Copper, mg 1.3 0.3
Calcium, mg 1000 294
1The supplement consisted of ground peanuts, dried skim milk, vegeta-
ble fat, sugar, multivitamin-mineral premix (Nutriset, France; www.nutriset.fr).
RDA, Recommended Dietary Allowance [Institute of Medicine (15)].
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ultraperformance liquid chromatography–tandem mass spectrome-
try (21). Briefly, samples were subjected to protein precipitation,
and nonpolar constituents were removed by liquid-liquid extraction
before analysis. Thiamin monophosphate (TMP), thiamin pyro-
phosphate (TPP), and free thiamin were measured by HPLC-
fluorescence detection after precolumn derivatization by using the
thiochrome method as described previously (22, 23) with a few
modifications. An Agilent Zorbax Eclipse Plus C18 column (4.6 3
150 mm, 5 mm) was used with an 8-min gradient of 0.15 mol
K2HPO4/L (pH 7.0; A) and methanol (B) as follows: 0 min, 15%
B; 1–3 min, 20% B; 3–6 min, 50% B; and 7–8 min, 15% B at
a flow rate of 1.5 mL/min, which allowed the simultaneous detection
of TPP, TMP, and thiamin derivatives. Vitamin B-12 concentrations
were measured by using the IMMULITE solid-phase, competitive
chemiluminescent enzyme immunoassay (24). Thiamin was calcu-
lated as the sum of combined free thiamin, TMP, and TPP con-
centrations based on molecular weights: thiamin = free thiamin +
(TMP 3 0.871) + (TPP 3 0.707). Riboflavin was calculated as the
TABLE 2
Characteristics of participants in the Breastfeeding, Antiretrovirals, and Nutrition study at the initial time point1
Treatment group
Control LNS ARV ARV + LNS
Characteristic n Value n Value n Value n Value
Age, y 176 25.5 (22.9–29.8)2 183 26.2 (22.2–29.9) 85 27.0 (24.0–29.4) 90 25.0 (22.9–30.0)
Postprimary education, % 177 36.7 185 37.8 85 35.3 90 32.2
Literacy, % 172 78.5 179 75.4 81 76.5 85 77.6
Married, % 177 90.4 185 90.3 85 89.4 90 92.2
Vaginal delivery, % 177 96.6 185 95.7 85 96.5 90 94.4
Anthropometric measurements
Height, cm 177 157 (154–160) 185 155 (152–159) 85 157 (154–160) 90 157 (154–161)
Weight, kg 177 55.5 (50.0–60.3) 185 54.4 (50.3–59.1) 85 54.6 (50.5–60.2) 90 54.5 (50.2–60.4)
BMI, kg/m2 177 22.4 (20.7–24.1) 185 22.3 (20.9–24.2) 85 22.3 (20.6–24.3) 90 22.2 (20.8–23.7)
Laboratory measurements
Hemoglobin, g/L 177 122 (111–131) 183 121 (111–131) 85 121 (107–126) 90 120 (111–131)
CD4 count, cells/mL 159 465 (319–665) 170 500 (337–738) 78 616 (439–780) 85 607 (412–796)
1ARV, antiretroviral; LNS, lipid-based nutrient supplement.
2Median; IQR in parentheses (all such values).
TABLE 3
Median concentrations (and IQRs) of thiamin, riboflavin, nicotinamide, pyridoxal, and vitamin B-12 in breast milk from HIV-infected women assigned to 1










(n = 90) LNS ARV LNS 3 ARV
Thiamin,3 mg/L 0.44 0.82 0.53
2 or 6 wk 176 (130–220)4 178 (144–212) 169 (123–215) 173 (134–229)
24 wk 199 (160–238) 208 (174–241) 202 (176–238) 201 (165–242)
Riboflavin,5 mg/L ,.001 0.071 0.015
2 or 6 wk 100 (71–147) 133 (87–184) 104 (74–132) 114 (81–148)
24 wk 94 (69–124) 129 (88–168) 95 (66–127) 102 (67–163)
Nicotinamide, mg/L 0.001 ,0.001 0.12
2 or 6 wk 430 (244–689) 566 (374–793) 386 (248–519) 404 (253–708)
24 wk 219 (124–358) 281 (169–457) 161 (102–268) 188 (97–315)
Pyridoxal, mg/L ,0.001 0.006 0.12
2 or 6 wk 62 (40–99) 84 (57–109) 56 (39–80) 64 (50–89)
24 wk 113 (82–150) 142 (100–190) 110 (77–152) 120 (83–161)
Vitamin B-12, mg/L 0.0018 0.0036 0.16
2 or 6 wk 0.33 (0.22–0.59) 0.41 (0.26–0.81) 0.29 (0.20–0.55) 0.30 (0.23–0.49)
24 wk 0.24 (0.19–0.35) 0.32 (0.23–0.49) 0.23 (0.19–0.33) 0.28 (0.21–0.39)
1Main effects and interactions of LNS and ARV were tested by ANOVA. A mixed-model repeated-measures analysis was used to test for the main effect
of time and interactions between treatment variables and time (no interactions with time were significant). ARV, antiretroviral; LNS, lipid-based nutrient
supplement; n, number of samples.
2P values represent both time points because of no significant LNS 3 ARV 3 time interaction.
3Thiamin = thiamin 1 (thiamin monophosphate 3 0.871) 1 (thiamin pyrophosphate 3 0.707).
4Median; IQR in parentheses (all such values).
5Riboflavin = riboflavin 1 (flavin adenine dinucleotide 3 0.479).
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sum of the combined free riboflavin and FAD concentrations, also
based on molecular weights: riboflavin = free riboflavin + (FAD 3
0.479) (25, 26).
Statistical analysis
The outcomes were concentrations of thiamin, riboflavin,
nicotinamide, pyridoxal, and vitamin B-12 in breast milk within
the 4 defined groups (antiretrovirals + LNSs, antiretrovirals,
LNSs, and control). SAS statistical software 9.4 (SAS Institute)
was used for all statistical analyses. Logarithmic transformations
were performed on thiamin, riboflavin, nicotinamide, and vitamin
B-12, and square root transformations were performed on pyr-
idoxal concentrations to normalize the distributions. The original
hypothesis considered only outcomes due to LNS supplemen-
tation. However, preliminary data showed significant effects of
antiretrovirals for some of the micronutrients; therefore, possible
negative interactions with antiretrovirals were also analyzed.
Mixed-model repeated-measures ANOVA (MIXED procedure)
was used to fit a 3-factor model, which included LNSs and
antiretrovirals as between-subject main effects, time as a within-
subject main effect, all 2- and 3-factor interactions, and a random
effect of subject, assuming an unstructured covariance matrix.
Because no significant interactions with time were observed, the
2 time points were pooled to assess the effect of treatment. For
outcomes with a significant interaction (P, 0.05) between LNSs
and antiretrovirals, pairwise comparisons were performed, ad-
justed for multiple comparisons with Tukey-Kramer’s test;
otherwise, only main effects were examined. Breast-milk B vi-
tamin concentrations were also compared with the values used
by the Institute of Medicine to set recommended intakes for
infants from 0 to 6 mo of age (15). P values ,0.05 were con-
sidered to be statistically significant.
RESULTS
Maternal characteristics at initial visit
No differences were observed in the characteristics of study
participants among the groups at the initial time point (Table 2).
FIGURE 1 Relative mean concentrations and 95% CIs of B vitamins in the treatment groups. Main effects (LNS 2 no LNS; ARV – no ARV) and
interactions between LNS, ARV, and time were tested by mixed-model repeated-measures ANOVA. No interactions with time were significant. Significant
main effects of LNS: **P , 0.01, ***P , 0.001. Significant main effects of ARVs: ++P, 0.01, +++P , 0.001. xSignificant ARV3 LNS interaction: pairwise
comparisons were adjusted for multiple comparisons with Tukey-Kramer’s test, LNS significantly increased riboflavin concentrations (P , 0.0001 when
compared with the control and ARV groups; P = 0.015 when compared with the ARV + LNS group), and no significant differences were observed between the
3 remaining groups. Control group: n = 177; LNS group: n = 185; ARV group: n = 85; ARV + LNS group: n = 91. ARV, antiretroviral; LNS, lipid-based
nutrient supplement.
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The average BMI was within the normal range. Overall com-
pliance with antiretroviral treatment and supplementation was
high. Mothers self-reported that they took their prescribed an-
tiretroviral treatment 89% of the time and LNS supplement 92%
of the time, based on adherence reports collected over 5 follow-
up visits. The self-reported frequency of EBF was 96% at 21 wk
postpartum (8, 11).
Overall treatment effects and time interaction
The results of the mixed model showed that the concentrations
of all vitamins changed over time (P , 0.012 for all). However,
none of the interactions involving time were significant, which
indicated that the effects of antiretrovirals and LNSs at 2 or 6 wk
were not different from the effects at 24 wk; therefore, we
pooled the data from the 2 time points for the statistical analysis.
A positive overall effect of LNSs on all vitamins, except thia-
min, and a negative overall effect of antiretrovirals on nicotin-
amide, pyridoxal, and vitamin B-12 were observed. The LNS 3
antiretroviral interaction was significant for riboflavin only (P =
0.015; Table 3).
Treatment effects at 2 or 6 and 24 wk
Concentrations of the nutrients in milk varied widely among
women in every treatment group, independently of the time of
collection. All women assigned to receive LNSs started at or very
close to delivery. Interactions between antiretrovirals and LNSs
were observed only for riboflavin (Table 3). The main effects of
LNSs and antiretrovirals were significant for nicotinamide,
pyridoxal, and vitamin B-12, but not for thiamin (Figure 1).
Whereas LNS consumption resulted in significantly higher
concentrations, antiretroviral treatment lowered the amounts of
these 3 vitamins in breast milk. Riboflavin concentrations in-
creased with LNSs when compared with antiretrovirals, anti-
retrovirals + LNSs, and the control treatment (P, 0.016 for all),
but were not influenced by antiretrovirals regimen alone. No
significant differences were observed between the antiretrovirals,
antiretrovirals + LNSs, and control groups. Neither LNS nor
antiretroviral treatment affected thiamin concentrations. The
consumption of antiretrovirals with LNSs eliminated the positive
effects of LNS supplementation on all vitamins but thiamin, i.e.,
the resulting milk concentrations were reduced to the concentra-
tion of the control group.
Comparison of milk B vitamin concentrations at 24 wk
with values used to set the AI for infants aged 0–6 mo
In comparison with the concentrations used to estimate the
AI for infants aged 0–6 mo (Table 4) (15), only 50–56% of the
samples met the estimated value for thiamin concentration in
milk regardless of treatment group. For pyridoxal, 60% of the
samples of the LNS group reached the values used to set the
AIs, whereas only 36–44% of the samples were adequate in
the remaining treatment groups. In contrast, ,2% of samples
met the AI milk values for riboflavin (0.6–1.6%) and nico-
tinamide (0–1.6%) in any group; 16–22% met vitamin B-12
assumptions, which increased to 34% when mothers were given
LNSs alone.
DISCUSSION
On the basis of strong evidence of the benefits of EBF during
the first 6 mo of life, it is crucial to understand how factors such
as maternal micronutrient intake, status, supplementation, and
antiretroviral therapy affect breast-milk concentrations of nu-
trients during the period of lactation. In areas where dietary intake
alone may not be sufficient to guarantee an adequate supply of
vitamins in milk, maternal supplementation may help to ensure
adequate nutrition of the infant. LNSs have been used historically
in the clinical setting for the treatment of severe acute malnu-
trition in children and are currently being evaluated in trials
aimed at improving birth and health outcomes in infants and
children with moderate malnutrition (18, 27). In this trial, LNSs
mitigated maternal weight loss, even in women receiving anti-
retrovirals (11).
These results suggest that the usual maternal intake of all of
the vitamins measured is insufficient, given the observation that
,1% of control samples reached the concentration used to set
the AI values for riboflavin and nicotinamide and only 16–50%
of samples met the AI values for any of the other B vitamins.
However, given that AIs are based on studies with small sample
sizes collected under unclear and variable conditions (12), the
true reference nutrient contents of breast milk and subsequently
the requirements of infants during the first 6 mo of life remain
somewhat uncertain.
Maternal LNS supplementation increased breast-milk con-
centrations of riboflavin, nicotinamide, pyridoxal, and vitamin
B-12. However when concentrations were compared with the
values used to set the AI (15, 28), only 2–60% of the partici-
pants receiving LNSs alone met the AI estimates across all the
vitamins measured. Therefore, only a limited amount of the
micronutrients in maternal LNSs get transferred to the infant
TABLE 4
Percentage of samples meeting the values used to set the AI for each












2 or 6 wk 200 35 35 31 36
24 wk 200 50 56 52 50
Riboflavin,3 %
2 or 6 wk 350 0 3.2 0 0
24 wk 350 0.6 1.6 1.2 1.1
Nicotinamide, %
2 or 6 wk 1800 2.8 5.4 1.2 1.1
24 wk 1800 0 1.6 0 1.1
Pyridoxal, %
2 or 6 wk 130 9.0 17 5.9 7.8
24 wk 130 36 60 44 41
Vitamin B-12, %
2 or 6 wk 0.42 35 47 33 33
24 wk 0.42 16 34 17 22
1AI, Adequate Intake; ARV, antiretroviral; LNS, lipid-based nutrient
supplement; n, number of samples.
2Thiamin = thiamin 1 (thiamin monophosphate 3 0.871) 1 (thiamin
pyrophosphate 3 0.707).
3Riboflavin = riboflavin 1 (flavin adenine dinucleotide 3 0.479).
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via breast milk and may not fulfill the infant’s requirements.
Duggan et al. also observed significantly higher vitamin B-12
concentrations in breast milk collected at 6 wk, but not at 3 or
6 mo postpartum after a daily maternal supplement consumption
of 50 mg/d during pregnancy through 6 wk postpartum (29).
This supplementation regimen resulted in a median breast-milk
vitamin B-12 concentration of only 136 pmol/L (0.18 mg/L) vs.
87 pmol/L, less than half of the value assumed to set the AI.
Even a daily maternal supplementation of 250 mg/d during
pregnancy up to 3 mo postpartum (30) resulted in a median
vitamin B-12 concentration at 3 mo of 235 pmol/L (0.32 mg/L)
vs. 170 pmol/L, which indicated a limitation of vitamin transfer
into breast milk. Recommendations regarding antiretroviral use
during lactation were introduced in the 2010 WHO guidelines in
response to evidence of a reduced risk of postnatal transmission
of HIV through breastfeeding when antiretrovirals are given to
either the HIV-infected mother or the HIV-exposed infant (1).
Thus, it is important to understand the effect of these treatments
on the concentrations of nutrients in breast milk and the potential
effect on the exclusively breastfed infant. Some antiretrovirals
given to the mother do appear in breast milk. In a study conducted
in Botswana, the concentrations of nevirapine, lamivudine, and
zidovudine were 0.67, 3.34, and 3.21 times, respectively, the
concentrations in maternal serum (31). Whereas these drugs were
also found in breast milk analyzed within the Breastfeeding,
Antiretrovirals, and Nutrition study, only lamivudine was detected
in infant plasma (32). However, it has been shown that infants
exposed to the maternal antiretroviral regimen through breast
milk developed HIV-1 drug resistance, which indicated the need
for close monitoring of the infants’ HIV status and to consider the
maternal regimen when deciding on infant treatment (33). These
findings are important in the context of Option B+, which pro-
vides lifelong antiretroviral therapy to pregnant and/or lactating
women as soon as HIV is diagnosed, regardless of their baseline
CD4 count, as recommended by the WHO (34, 35). Although
Option B+ aids considerably in the Prevention of Mother-to-Child
Transmission program in resource-limited countries with a high
prevalence of HIV, it has been shown that micronutrients such as
vitamin D and B-12 can be negatively affected by antiretrovirals
based on lower plasma concentrations (36–38). These observa-
tions call attention to the need to measure effects of Option B+ on
maternal and infant vitamin status.
LNSs increased all B vitamin concentrations in breast milk,
except thiamin. Antiretroviral treatment without LNS supple-
mentation negatively affected the concentrations of nicotinamide,
pyridoxal, and vitamin B-12. When LNS was taken with anti-
retroviral treatment, the positive effect of supplementation was
offset by the negative effect of the antiretrovirals on nicotinamide,
pyridoxal, and vitamin B-12, which resulted in vitamin concen-
trations that were comparable with those in the control group. Even
though antiretroviral treatment alone did not affect milk riboflavin
concentrations, the combination of antiretrovirals with LNSs pre-
vented LNS-induced increases in this vitamin. These results suggest
that antiretroviral treatment negatively influences the uptake or
transfer of certain B vitamins in breast milk and that LNS sup-
plementation of lactating women receiving antiretrovirals may be
beneficial to breast-milk vitamin concentrations and subsequently
to infants who are exclusively breastfed. It remains to be determined
whether the timing of taking supplements and antiretrovirals might
improve the benefits of micronutrient supplementation.
Even though the number ofmilk samples analyzed in the current
study is extensive, they may not be representative of 24-h milk
production, because the samples were not obtained by emptying
the breast. No information is available about the timing of the last
infant feed or LNS consumption, but usually there is relatively little
variability in B vitamin concentrations during a feed. In addition,
because our initial sampleswere from 2 or 6wk, the actual effect of
the treatments from 0 to 2 wk and 0 to 6 wk is not reflected in the
analysis. Nevertheless, we concluded that LNS supplementation
had a positive effect on breast-milk concentrations of all B vita-
mins analyzed, except thiamin, whereas antiretroviral treatment
affected B vitamin uptake into breast milk. Additional studies are
necessary to gain a better understanding of the interactions be-
tween maternal antiretroviral treatment and micronutrient sup-
plementation and their long-term effects on breast-milk vitamin
concentrations and maternal and infant status. In addition, more
information is desirable about the effect of different levels of
supplemental nutrients, and the optimal timing of supplementation
during pregnancy or lactation, in healthy women and in the context
of HIV infection.
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